{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T02:06:36Z","timestamp":1772762796950,"version":"3.50.1"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1093\/pch\/19.2.91","type":"journal-article","created":{"date-parts":[[2017,3,15]],"date-time":"2017-03-15T22:38:56Z","timestamp":1489617536000},"page":"91-94","source":"Crossref","is-referenced-by-count":5,"title":["Immunization for meningococcal serogroup B: What does the practitioner need to know?"],"prefix":"10.1093","volume":"19","author":[{"given":"Joan L","family":"Robinson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t20170406134545_b1-pch19091","unstructured":"Public Health Agency of Canada 2012 Invasive meningococcal disease (IMD), Figure 2 www.phac-aspc.gc.ca\/im\/vpd-mev\/meningococcal-eng.php (Accessed December 16, 2013)."},{"issue":"1","key":"key\n\t\t\t\t20170406134545_b2-pch19091","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/INF.0b013e3182706b89","article-title":"The disease burden of invasive meningococcal serogroup B disease in Canada","volume":"32","author":"Bettinger","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"6","key":"key\n\t\t\t\t20170406134545_b3-pch19091","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: A randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"issue":"9869","key":"key\n\t\t\t\t20170406134545_b4-pch19091","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: Results of two randomised trials","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170406134545_b5-pch19091","article-title":"Catch-up vaccination of healthy toddlers with an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) \u2013 Exploration of a two-dose schedule","author":"Prymula"},{"issue":"9816","key":"key\n\t\t\t\t20170406134545_b6-pch19091","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: A phase 2b\/3 randomised, observer-blind, placebo-controlled study","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"issue":"8","key":"key\n\t\t\t\t20170406134545_b7-pch19091","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/pch\/16.8.e61","article-title":"From genes to vaccine: A breakthrough in the prevention of meningococcal group B disease","volume":"16","author":"Major","year":"2011","journal-title":"Paediatr Child Health"},{"issue":"15","key":"key\n\t\t\t\t20170406134545_b8-pch19091","doi-asserted-by":"crossref","first-page":"E715","DOI":"10.1503\/cmaj.130257","article-title":"Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose","volume":"185","author":"Snape","year":"2013","journal-title":"CMAJ"},{"key":"key\n\t\t\t\t20170406134545_b9-pch19091","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.vaccine.2013.03.063","article-title":"Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)","volume":"32","author":"Bettinger","year":"2013","journal-title":"Vaccine"},{"issue":"3","key":"key\n\t\t\t\t20170406134545_b10-pch19091","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/cid\/cis892","article-title":"Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity","volume":"56","author":"Kristiansen","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"5","key":"key\n\t\t\t\t20170406134545_b11-pch19091","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1128\/CVI.00529-09","article-title":"Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: Effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity","volume":"17","author":"Campbell","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"key\n\t\t\t\t20170406134545_b12-pch19091","article-title":"Impact of a quadrivalent conjugate (MENACWY-CRM) or a serogroup B (4CMENB) meningococcal vaccine on meningococcal carriage in English university students. Abstract 1472","author":"Read"},{"key":"key\n\t\t\t\t20170406134545_b13-pch19091","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/1471-2334-12-202","article-title":"Epidemiology of serogroup B invasive meningococcal disease in Ontario, Canada, 2000 to 2010","volume":"12","author":"Dang","year":"2012","journal-title":"BMC Infect Dis"},{"key":"key\n\t\t\t\t20170406134545_b14-pch19091","article-title":"Prophylactic paracetamol in infants decreases fever following concomitant administration of an investigational meningococcal serogroup B vaccine with routine immunisations. Poster 631","author":"Prymula"},{"issue":"9","key":"key\n\t\t\t\t20170406134545_b15-pch19091","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","article-title":"Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): A case-control study","volume":"11","author":"Viner","year":"2012","journal-title":"Lancet Neurol"},{"issue":"5","key":"key\n\t\t\t\t20170406134545_b16-pch19091","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1128\/JCM.06835-11","article-title":"Invasive serogroup B Neisseria meningitidis in Quebec, Canada, 2003 to 2010: Persistence of the ST-269 clone since it first emerged in 2003","volume":"50","author":"Zhou","year":"2012","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20170406134545_b17-pch19091","unstructured":"Canadian Medical Protective Association 2009 (IS0887-E). New vaccines \u2013 What are your obligations?: An article for physicians by physicians: www.cmpa-acpm.ca\/cmpapd04\/docs\/resource_files\/infosheets\/2008\/com_is0887-e.cfm (Accessed November 12, 2013)."}],"container-title":["Paediatrics & Child Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/pch\/article-pdf\/19\/2\/91\/11188049\/pch19091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T01:34:01Z","timestamp":1503624841000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pch\/article-lookup\/doi\/10.1093\/pch\/19.2.91"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"URL":"https:\/\/doi.org\/10.1093\/pch\/19.2.91","relation":{},"ISSN":["1205-7088","1918-1485"],"issn-type":[{"value":"1205-7088","type":"print"},{"value":"1918-1485","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2]]}}}